Benign prostatic hyperplasia (BPH) is a common condition in older men, with its prevalence increasing as age advances. Chronic inflammation orchestrates oxidative stress to exacerbate BPH. YAP1, which regulates organ size, cellular homeostasis, and tissue fibrosis, can be activated by ROCK1. Given the urgent clinical need for more effective therapies, this study explored whether targeting the ROCK1/YAP1 axis could mitigate BPH progression. Here, rats received in situ adeno-associated virus (AAV) injection to induce prostate-specific YAP1 overexpression. An inflammation-associated experimental autoimmune prostatitis (EAP) model was established by prostate antigen immunisation, followed by treatment with ROCK1 inhibitor fasudil and YAP1 inhibitor verteporfin. Cell models were treated with specific inhibitors to confirm the critical role of YAP1 in modulating mitochondrial function. As a result, YAP1 overexpression was sufficient to induce a pathological BPH phenotype. Specifically, YAP1 activated the inflammatory cascade to provoke an immune response, disrupted proliferation/apoptosis balance to induce tissue hyperplasia, triggered epithelial-mesenchymal transition (EMT) and reactive stroma to drive fibrosis, and promoted NOX4/ROS generation and antioxidant depletion to cause oxidative stress. The inflammation-induced experimental autoimmune prostatitis (EAP) model also presented analogous BPH lesions, which were significantly alleviated when treated with ROCK1 inhibitor fasudil and YAP1 inhibitor verteporfin. Mechanistically, YAP1 activation under inflammatory conditions suppressed SIRT1 expression, thereby exacerbating oxidative stress through the disruption of DRP1/MFN2-mediated mitochondrial dynamics. Overall, inflammation-driven activation of the ROCK1/YAP1 axis aggravates oxidative stress, promoting BPH hyperplasia and fibrosis by impairing SIRT1-regulated mitochondrial dynamics. These findings provide a preclinical rationale for developing ROCK1 or YAP1 inhibitors as targeted therapies for BPH patients with chronic inflammation.
| [1] |
S. Xia, X. Xu, J. Teng, C. Xu, and X. Tang, “Characteristic Pattern of Human Prostatic Growth With Age,” Asian Journal of Andrology 4, no. 4 (2002): 269–271.
|
| [2] |
J. C. Nickel, C. G. Roehrborn, R. Castro-Santamaria, S. J. Freedland, and D. M. Moreira, “Chronic Prostate Inflammation Is Associated With Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention,” Journal of Urology 196, no. 5 (2016): 1493–1498.
|
| [3] |
F. Di Silverio, C. Bosman, M. Salvatori, et al., “Combination Therapy With Rofecoxib and Finasteride in the Treatment of Men With Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH),” European Urology 47, no. 1 (2005): 72–78, discussion 78–79.
|
| [4] |
R. E. Vickman, L. Aaron-Brooks, R. Zhang, et al., “TNF Is a Potential Therapeutic Target to Suppress Prostatic Inflammation and Hyperplasia in Autoimmune Disease,” Nature Communications 13, no. 1 (2022): 2133.
|
| [5] |
M. Zhang, C. Luo, K. Cui, T. Xiong, and Z. Chen, “Chronic Inflammation Promotes Proliferation in the Prostatic Stroma in Rats With Experimental Autoimmune Prostatitis: Study for a Novel Method of Inducing Benign Prostatic Hyperplasia in a Rat Model,” World Journal of Urology 38, no. 11 (2020): 2933–2943.
|
| [6] |
M. Zhang, D. Lin, C. Luo, P. Wei, K. Cui, and Z. Chen, “Tissue Kallikrein Protects Rat Prostate Against the Inflammatory Damage in a Chronic Autoimmune Prostatitis Model via Restoring Endothelial Function in a Bradykinin Receptor B2-Dependent Way,” Oxidative Medicine and Cellular Longevity 2022 (2022): 1247806.
|
| [7] |
F. X. Yu, B. Zhao, and K. L. Guan, “Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer,” Cell 163, no. 4 (2015): 811–828.
|
| [8] |
Z. Liu, S. Li, S. Chen, et al., “YAP-Mediated GPER Signaling Impedes Proliferation and Survival of Prostate Epithelium in Benign Prostatic Hyperplasia,” IScience 27, no. 3 (2024): 109125.
|
| [9] |
T. Yang, J. Yuan, Y. Peng, et al., “Metformin: A Promising Clinical Therapeutical Approach for BPH Treatment via Inhibiting Dysregulated Steroid Hormones-Induced Prostatic Epithelial Cells Proliferation,” Journal of Pharmaceutical Analysis 14, no. 1 (2024): 52–68.
|
| [10] |
D. Lin, C. Luo, P. Wei, et al., “YAP1 Recognizes Inflammatory and Mechanical Cues to Exacerbate Benign Prostatic Hyperplasia via Promoting Cell Survival and Fibrosis,” Advanced Science 11, no. 5 (2024): e2304274.
|
| [11] |
Y. Cheng, P. Huang, Q. Zou, H. Tian, Q. Cheng, and H. Ding, “Nicotinamide Mononucleotide Alleviates Seizures via Modulating SIRT1-PGC-1alpha Mediated Mitochondrial Fusion and Fission,” Journal of Neurochemistry 168, no. 12 (2024): 3962–3981.
|
| [12] |
M. Giacomello, A. Pyakurel, C. Glytsou, and L. Scorrano, “The Cell Biology of Mitochondrial Membrane Dynamics,” Nature Reviews. Molecular Cell Biology 21, no. 4 (2020): 204–224.
|
| [13] |
R. A. Kowluru and K. Alka, “Mitochondrial Quality Control and Metabolic Memory Phenomenon Associated With Continued Progression of Diabetic Retinopathy,” International Journal of Molecular Sciences 24, no. 9 (2023): 8076.
|
| [14] |
X. Chang, Y. Li, C. Cai, et al., “Mitochondrial Quality Control Mechanisms as Molecular Targets in Diabetic Heart,” Metabolism 137 (2022): 155313.
|
| [15] |
I. M. Fuentes, A. N. Pierce, P. T. O'Neil, and J. A. Christianson, “Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation,” Journal of Visualized Experiments 102 (2015): e53181.
|
| [16] |
D. Lin, M. Zhang, C. Luo, P. Wei, K. Cui, and Z. Chen, “Targeting Ferroptosis Attenuates Inflammation, Fibrosis, and Mast Cell Activation in Chronic Prostatitis,” Journal of Immunology Research 2022 (2022): 6833867.
|
| [17] |
K. E. Andersson, R. Soler, and C. Fullhase, “Rodent Models for Urodynamic Investigation,” Neurourology and Urodynamics 30, no. 5 (2011): 636–646.
|
| [18] |
R. Qi, Y. Wang, F. Yan, and J. Zhong, “Exosomes Derived From ITGB1 Modified Telocytes Alleviates LPS-Induced Inflammation and Oxidative Stress Through YAP1/ROS Axis,” Heliyon 10, no. 5 (2024): e27086.
|
| [19] |
H. R. Li, Q. Liu, C. L. Zhu, et al., “Beta-Nicotinamide Mononucleotide Activates NAD+/SIRT1 Pathway and Attenuates Inflammatory and Oxidative Responses in the Hippocampus Regions of Septic Mice,” Redox Biology 63 (2023): 102745.
|
| [20] |
H. Amano, A. Chaudhury, C. Rodriguez-Aguayo, et al., “Telomere Dysfunction Induces Sirtuin Repression That Drives Telomere-Dependent Disease,” Cell Metabolism 29, no. 6 (2019): 1274, e1279–1290.
|
| [21] |
W. Ou, W. Xu, F. Liu, et al., “Increased Expression of Yes-Associated Protein/YAP and Transcriptional Coactivator With PDZ-Binding Motif/TAZ Activates Intestinal Fibroblasts to Promote Intestinal Obstruction in Crohn's Disease,” eBioMedicine 69 (2021): 103452.
|
| [22] |
T. Kashihara, R. Mukai, S. I. Oka, et al., “YAP Mediates Compensatory Cardiac Hypertrophy Through Aerobic Glycolysis in Response to Pressure Overload,” Journal of Clinical Investigation 132, no. 6 (2022): e150595.
|
| [23] |
A. Mondal, S. Das, J. Samanta, S. Chakraborty, and A. Sengupta, “YAP1 Induces Hyperglycemic Stress-Mediated Cardiac Hypertrophy and Fibrosis in an AKT-FOXM1 Dependent Signaling Pathway,” Archives of Biochemistry and Biophysics 722 (2022): 109198.
|
| [24] |
A. Pocaterra, G. Santinon, P. Romani, et al., “F-Actin Dynamics Regulates Mammalian Organ Growth and Cell Fate Maintenance,” Journal of Hepatology 71, no. 1 (2019): 130–142.
|
| [25] |
S. Satoh, I. Ikegaki, K. Kawasaki, T. Asano, and M. Shibuya, “Pleiotropic Effects of the Rho-Kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies,” Current Vascular Pharmacology 12, no. 5 (2014): 758–765.
|
| [26] |
R. M. Vicari, B. Chaitman, D. Keefe, et al., “Efficacy and Safety of Fasudil in Patients With Stable Angina: A Double-Blind, Placebo-Controlled, Phase 2 Trial,” Journal of the American College of Cardiology 46, no. 10 (2005): 1803–1811.
|
| [27] |
Y. Cao, Y. Wang, W. Li, et al., “Fasudil Attenuates Oxidative Stress-Induced Partial Epithelial-Mesenchymal Transition of Tubular Epithelial Cells in Hyperuricemic Nephropathy via Activating Nrf2,” European Journal of Pharmacology 975 (2024): 176640.
|
| [28] |
C. Liu, S. Guo, R. Liu, et al., “Fasudil-Modified Macrophages Reduce Inflammation and Regulate the Immune Response in Experimental Autoimmune Encephalomyelitis,” Neural Regeneration Research 19, no. 3 (2024): 671–679.
|
| [29] |
L. S. Lim, P. Mitchell, J. M. Seddon, F. G. Holz, and T. Y. Wong, “Age-Related Macular Degeneration,” Lancet 379, no. 9827 (2012): 1728–1738.
|
| [30] |
Y. Liu-Chittenden, B. Huang, J. S. Shim, et al., “Genetic and Pharmacological Disruption of the TEAD-YAP Complex Suppresses the Oncogenic Activity of YAP,” Genes & Development 26, no. 12 (2012): 1300–1305.
|
| [31] |
A. M. Barrette, H. Ronk, T. Joshi, et al., “Anti-Invasive Efficacy and Survival Benefit of the YAP-TEAD Inhibitor Verteporfin in Preclinical Glioblastoma Models,” Neuro-Oncology 24, no. 5 (2022): 694–707.
|
| [32] |
J. Yang, S. Li, Z. Li, et al., “Targeting YAP1-Regulated Glycolysis in Fibroblast-Like Synoviocytes Impairs Macrophage Infiltration to Ameliorate Diabetic Osteoarthritis Progression,” Advanced Science 11, no. 5 (2024): e2304617.
|
| [33] |
F. Calvo, N. Ege, A. Grande-Garcia, et al., “Mechanotransduction and YAP-Dependent Matrix Remodelling Is Required for the Generation and Maintenance of Cancer-Associated Fibroblasts,” Nature Cell Biology 15, no. 6 (2013): 637–646.
|
| [34] |
P. L. Minciullo, A. Inferrera, M. Navarra, G. Calapai, C. Magno, and S. Gangemi, “Oxidative Stress in Benign Prostatic Hyperplasia: A Systematic Review,” Urologia Internationalis 94, no. 3 (2015): 249–254.
|
| [35] |
P. Yue, Y. Zhang, L. Liu, et al., “Yap1 Modulates Cardiomyocyte Hypertrophy via Impaired Mitochondrial Biogenesis in Response to Chronic Mechanical Stress Overload,” Theranostics 12, no. 16 (2022): 7009–7031.
|
| [36] |
H. Wan, Y. Wang, Q. Pan, et al., “Quercetin Attenuates the Proliferation, Inflammation, and Oxidative Stress of High Glucose-Induced Human Mesangial Cells by Regulating the miR-485-5p/YAP1 Pathway,” International Journal of Immunopathology and Pharmacology 36 (2022): 20587384211066440.
|
| [37] |
T. G. Biel, S. Lee, J. A. Flores-Toro, et al., “Sirtuin 1 Suppresses Mitochondrial Dysfunction of Ischemic Mouse Livers in a Mitofusin 2-Dependent Manner,” Cell Death and Differentiation 23, no. 2 (2016): 279–290.
|
| [38] |
W. Dong, L. Yan, Y. Tan, et al., “Melatonin Improves Mitochondrial Function by Preventing Mitochondrial Fission in Cadmium-Induced Rat Proximal Tubular Cell Injury via SIRT1-PGC-1alpha Pathway Activation,” Ecotoxicology and Environmental Safety 242 (2022): 113879.
|
| [39] |
L. Hu, M. Ding, D. Tang, et al., “Targeting Mitochondrial Dynamics by Regulating Mfn2 for Therapeutic Intervention in Diabetic Cardiomyopathy,” Theranostics 9, no. 13 (2019): 3687–3706.
|
| [40] |
M. A. Rogers, N. Maldonado, J. D. Hutcheson, et al., “Dynamin-Related Protein 1 Inhibition Attenuates Cardiovascular Calcification in the Presence of Oxidative Stress,” Circulation Research 121, no. 3 (2017): 220–233.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.
PDF
(21066KB)
